Drug Profile
Research programme: antifungals - Ranbaxy
Alternative Names: RBx 4467; RBx 7635; RBx 9050Latest Information Update: 21 Oct 2008
Price :
$50
*
At a glance
- Originator Ranbaxy Laboratories
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 20 Oct 2008 Ranbaxy Laboratories has been acquired by Daiichi Sankyo Company
- 03 Feb 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the Mycoses pharmacodynamics and antimicrobial activity sections
- 12 Nov 2002 This programme is still in active development